AstraZeneca (AZN)

AstraZeneca’s largest therapeutic area is oncology, where it markets targeted cancer medicines and immuno-oncology treatments across a range of tumour types. Cancer care is a central part of the company’s growth strategy, supported by a deep research pipeline and a focus on precision medicine. The group also has major franchises in cardiovascular, renal, and metabolic diseases, including therapies aimed at conditions such as diabetes, heart failure, and chronic kidney disease.

Its rare disease business, expanded significantly through the acquisition of Alexion, gives AstraZeneca exposure to highly specialised medicines for smaller patient populations with serious disorders. The company is also active in respiratory and immunology, an area where it has long-standing expertise in asthma, chronic obstructive pulmonary disease, and related inflammatory conditions.

AstraZeneca sells branded medicines, meaning its performance depends on clinical innovation, regulatory approvals, patent protection, physician adoption, reimbursement, and competition from rival drugs or generics. Its revenue base is geographically diversified, with the United States representing a substantial share but not the majority of sales. For investors, AZN is a large-cap pharmaceutical stock tied to global drug development, speciality medicine, and long-cycle healthcare demand.